This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

PHILIP S. HENCH, M.D.

Arch Intern Med. 1932;49(1):1-25.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Shortly after Wright and others introduced specific vaccine therapy about twenty years ago, nonspecific vaccine therapy was introduced. This was soon followed by nonspecific protein therapy. Typhoid vaccine was first used intravenously by Kraus and Mazza¹ in Argentina about 1912. Its use as a preventive of typhoid fever was first advocated by Ichikawa² (1912), and it was first given intravenously as a nonspecific protein for "fever" therapy by Miller and Lusk³ in 1916 in the treatment for chronic infectious arthritis. It has since become one of the most widely used agents for protein or "fever" therapy, is employed for many diseases, particularly of the joints, skin and eyes, and as a substitute for malarial treatment in late syphilis. Recently it has been successfully used in the treatment for occlusive vascular disease⁴ and for evaluating, by means of the "vasomotor index" of Brown, the possibilities of sympathetic . . . [Full Text PDF of this Article]

Author Affiliations
ROCHESTER, MINN.

From the Division of Medicine, the Mayo Clinic.

Footnotes
Submitted for publication, March 2, 1931.

Read before the Section on Pharmacology and Therapeutics at the Eighty-First Annual Session of the American Medical Association, Detroit, June 27, 1930.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?